31 – 40 of 115
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain : rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial
(
- Contribution to journal › Article
-
Mark
Caregiver Burden and Quality of Life in Late Stage Parkinson’s Disease
(
- Contribution to journal › Article
-
Mark
Quality of life and resource utilization-Swedish data from the Care of Late-Stage Parkinsonism (CLaSP) study
(
- Contribution to journal › Article
-
Mark
Why do ‘OFF’ periods still occur during continuous drug delivery in Parkinson’s disease?
(
- Contribution to journal › Scientific review
-
Mark
High risk of developing dementia in Parkinson’s disease : a Swedish registry-based study
(
- Contribution to journal › Article
-
Mark
Safinamide in the treatment pathway of Parkinson’s Disease : a European Delphi Consensus
(
- Contribution to journal › Article
- 2021
-
Mark
The Non-Motor Symptoms Scale in Parkinson’s disease : Validation and use
(
- Contribution to journal › Scientific review
-
Mark
Longitudinal prediction of falls and near falls frequencies in Parkinson's disease:a prospective cohort study
(
- Contribution to journal › Article
-
Mark
Parkinson's Disease with Device, Diary, or in Disguise. Dyskinesia reduction, motor state evaluation, and workforce participation among persons with Parkinson's disease.
2021) In Lund University Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
-
Mark
Effects of safinamide on pain in patients with fluctuating Parkinson's disease
(
- Contribution to journal › Article